Research@UIC > Life Sciences Initiative > Announcement

Announcement

Catalyzing Collaboration
Between
Industry and Academia in the Life Sciences

Topic: Protein and Antibody Therapeutics

Date:              

Friday, June 26, 2009 Cancelled !
10:00 a.m. - 3:35 p.m. CST

Location:       

Rush University
Chicago, IL

Meet and network with people from all areas of the life sciences

Become part of an on-going forum bringing life science researchers from universities and industries together to exchange ideas, discuss challenges, and explore potential collaborations in an effort to promote commercialization. This forum will provide a unique combination of presentations, roundtable discussions, and networking. The intent is to expose industry to the wealth of available research and innovation taking place in the life sciences departments of participating universities. Industry participants have included Baxter, Abbott, TAP, Takeda, Eli Lilly, Rush University and University of Illinois at Chicago.

This is the Eighth in a series of forums intended to foster collaboration between Midwest area universities and pharmaceutical firms. Previous forum topics have ranged from neurodegenerative and reproductive disorders, to regenerative and cardiovascular medicine, and have resulted in collaborative efforts between industry and academia.

Register for this Forum via this link: www.research.uic.edu/air/registration.html

RESERVE EARLY; LIMITED SEATING!!!!!

Faculty members actively conducting research as it relates to Protein and Antibody Therapeutics are invited to submit a poster and/or abstract (in 250 words or less) in at least one of the following areas for review at: http://tigger.uic.edu/depts/ovcr/research/air/

• Clinical Diagnostic or Therapeutic Applications,
• New Research Methodologies or,
• Platform Technologies.
  

Submission website: 
http://tigger.uic.edu/depts/ovcr/research/air/submission.html

Presentation selection will be based upon the following Criteria:
Research topic stage of development -- 20%
Potential to discover/develop critical medical outcomes through research topic -- 40%
Potential commercial impact of research topic -- 40%

Please contact with questions: Ronald L. Kirschner, M.D. at ron.kirschner@comcast.net.
Submit all abstracts at the above website.